- Home
- AQST vs GOSS Comparison
AQST vs GOSS Comparison
Compare AQST & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | GOSS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | 142 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.0M | 615.7M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AQST | GOSS |
|---|---|---|
| Price | $4.07 | $0.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $9.00 | $4.91 |
| AVG Volume (30 Days) | 2.0M | ★ 26.4M |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.81 |
| EPS | N/A | ★ N/A |
| Revenue | $67,430,000.00 | ★ $114,701,000.00 |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $58.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.20 | $0.33 |
| 52 Week High | $7.55 | $3.87 |
Technical Indicators
Market Signals| Indicator | AQST | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 22.54 |
| Support Level | $3.69 | $0.33 |
| Resistance Level | $4.46 | $0.60 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 30.09 | 51.86 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.